Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.
You may also be interested in...
Regulatory And Policy News, In Brief
Endo's Advisory Committee Cancelled
Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves
A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.
Portola/Novartis Plan Phase III Trial For Elinogrel, With Eyes For Plavix Market
Portola's anti-thrombotic vision: Execs discuss possibilities for two partnered, Phase III ready drugs - elinogrel and betrixaban.